DEPARTMENT NAME

Core Laboratory

GENERAL INFORMATION

Hours of	Daily, 24 hours
Operation:	
Location:	Room B403, RRUCLA
Phone:	(310) 267-8100
Key Personnel:	Medical Director: Alyssa Ziman, MD (310) 267-8090; B403M, RRUCLA
	Co-chiefs, Clinical Chemistry: Lu Song, PhD (310) 267-8169; B403L, RRUCLA Imir Metushi, PhD (310) 794-7586; A3-231S, CHS
	Chief, Hematology: Nam Ku, MD (310) 825-7435; AS-325, CHS
	Point of Care: Omai Garner, PhD (310) 794-8748
	Laboratory Manager: Marivic Visico (310) 267-8102

SPECIMEN DELIVERY

Specimens should be delivered to Support Services located in 200 Medical Plaza, Suite 145 or via pneumatic tubes located throughout the Medical Center (RRUCLA). Specimens referred from outside clinics or institutions should be sent to the following address:

RRUCLA Medical Center, Westwood

Clinical Laboratory, Specimen Processing

200 Medical Plaza, Suite 145

Los Angeles, CA 90095-1713

TEST AVAILABILITY

Stat and routine testing are available 24 hours, 7 days/week. Special coagulation testing is performed Monday-Friday, 0800-1500.

TESTING

The Core Laboratory performs routine chemistry, hematology, and urinalysis, as well as routine and special coagulation testing. Core Laboratory personnel also provide point-of-care testing (POCT) oversight and quality control review for all hospital-licensed performing locations.

Routine chemistry tests are available to evaluate the following:

- Acid-base balance (electrolytes, blood gases, co-oximetry)
- Lipid metabolism
- Renal function
- Liver function
- Pancreatic function
- Acute coronary syndrome
- Congestive heart failure
- Iron status

Routine hematology tests are available to evaluate the following:

- Sickle cell screen
- Erythrocyte sedimentation rate
- Reticulated platelet fraction (immature platelet fraction [IPF])
- Immature Granulocytes (IG)
- Reticulocyte count
- Complete blood count (CBC) including platelet count (PLT)
- Peripheral blood cell differential
- RBC morphology
- Body fluid analysis count and differential
- Joint fluid crystal analysis

Special coagulation studies include but are not limited to:

- Coagulation factor assays
- Detection of hypercoagulable states, detection of factor inhibitors
- Platelet aggregation studies

Rapid tests include:

- COVID-19
- Flu A/B
- HIV ½ Antibody

Toxicology:

- Quantitative therapeutic drug monitoring
- Qualitative drugs of abuse (see below)

Drugs of abuse are reported as positive or negative. Confirmation testing is not available in house. Drugs of abuse screens are performed on urines. Screening is available for amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, fentanyl, hydrocodone, methadone, opiates, oxycodone, and PCP.